Anti-β2 glycoprotein I(anti-β2GPI)antibodies are important contributors to the development of thrombosis.Anti-β2GPI antibody complexes withβ2GPI are well known to activate monocytes and endothelial cells via the i...Anti-β2 glycoprotein I(anti-β2GPI)antibodies are important contributors to the development of thrombosis.Anti-β2GPI antibody complexes withβ2GPI are well known to activate monocytes and endothelial cells via the intracellular NF-kB pathway with prothrombotic implications.By contrast,the interaction of anti-β2GPI/β2GPI complexes with platelets has not been extensively studied.The p38 mitogen-activated protein kinase(MAPK)pathway has been recognized to be an important intracellular signaling pathway in the coagulation cascade and an integral component of arterial and venous thrombosis.The present study reveals that levels of anti-β2GPI/β2GPI complexes in sera are positively associated with p38MAPK phosphorylation of platelets in thrombotic patients.Furthermore,SB203580 inhibits anti-β2GPI/β2GPI complex-induced platelet activation.Thrombus formation decreased in p38MAPK−/−mice after treatment with anti-β2GPI/β2GPI complexes.In conclusion,p38MAPK may be a treatment target for anti-β2GPI antibody-associated thrombotic events.展开更多
目的探讨雷公藤多苷对Ig A肾病（Ig A nephropathy,Ig AN）患者血清离子及β2糖蛋白I（β2-glycoprotein,β2-GPI）/氧化低密度脂蛋白（oxidized low density lipoprotein,ox-LDL）的影响。方法收集丽水市人民医院肾内科2014年1月~2015...目的探讨雷公藤多苷对Ig A肾病（Ig A nephropathy,Ig AN）患者血清离子及β2糖蛋白I（β2-glycoprotein,β2-GPI）/氧化低密度脂蛋白（oxidized low density lipoprotein,ox-LDL）的影响。方法收集丽水市人民医院肾内科2014年1月~2015年4月收治的原发性Ig AN患者54例,随机分为对照组和实验组,每组27例,对照组患者常规给予盐酸贝那普利片10 mg,1次/天口服;给予双嘧达莫片50 mg,3次/天口服,实验组在对照组基础上给予雷公藤多苷片20 mg,3次/天口服。2组患者均治疗6个月。治疗结束后,对所有患者的血清Ca、P、β2-GPI/ox-LDL水平及肾功能相关指标进行检测。结果与对照组治疗后比较,实验组患者血清Ca水平较高,血清P水平较低（P〈0.05）;实验组患者的血清β2-GPI/ox-LDL水平较低（P〈0.05）;实验组患者的血清Scr、BUN水平较低（P〈0.05）。结论雷公藤多苷能够显著降低Ig AN患者血清P、β2-GPI/ox-LDL、Scr及BUN水平,提高血清Ca水平,改善肾功能。展开更多
基金This work was supported by a grant from the National Natural Science Foundation of China(No.81270394)awarded to Yanhong Liu and a grant from the Fundamental Research Founds for the Provincial Universities(No.2017LCZX67)awarded to Wenjing Zhang.
文摘Anti-β2 glycoprotein I(anti-β2GPI)antibodies are important contributors to the development of thrombosis.Anti-β2GPI antibody complexes withβ2GPI are well known to activate monocytes and endothelial cells via the intracellular NF-kB pathway with prothrombotic implications.By contrast,the interaction of anti-β2GPI/β2GPI complexes with platelets has not been extensively studied.The p38 mitogen-activated protein kinase(MAPK)pathway has been recognized to be an important intracellular signaling pathway in the coagulation cascade and an integral component of arterial and venous thrombosis.The present study reveals that levels of anti-β2GPI/β2GPI complexes in sera are positively associated with p38MAPK phosphorylation of platelets in thrombotic patients.Furthermore,SB203580 inhibits anti-β2GPI/β2GPI complex-induced platelet activation.Thrombus formation decreased in p38MAPK−/−mice after treatment with anti-β2GPI/β2GPI complexes.In conclusion,p38MAPK may be a treatment target for anti-β2GPI antibody-associated thrombotic events.
